Astrin Biosciences Announces Scientific Advisory Board to Advance Early Cancer Detection Leveraging AI and Proteomics
Astrin Biosciences, a cancer intelligence company, announced the formation of its Scientific Advisory Board on December 8, 2025.
The board comprises internationally recognized physicians and scientists from institutions including Dana-Farber Cancer Institute, George Washington University, Mayo Clinic, Montefiore Einstein Comprehensive Cancer Center, University of Pittsburgh, and Vanderbilt-Ingram Cancer Center.
Board members include experts in breast cancer, cancer genetics, liquid biopsy, cancer dormancy, gastrointestinal cancers, and radiology.
The board will guide Astrin in advancing early cancer detection, particularly its mission to make Stage 0 cancer detection routine.
This announcement follows the launch of Certitude™ Breast, the first non-imaging screening test to detect breast cancer as early as Stage 0.
Astrin's platform combines deep proteomics and AI, analyzing over 9,000 proteins from a blood sample to detect the earliest molecular signals of cancer development.